| Literature DB >> 33418437 |
Wesley C Van Voorhis1, Matthew A Hulverson2, Ryan Choi2, Wenlin Huang3, Samuel L M Arnold2, Deborah A Schaefer4, Dana P Betzer4, Rama S R Vidadala5, Sangun Lee6, Grant R Whitman2, Lynn K Barrett2, Dustin J Maly5, Michael W Riggs4, Erkang Fan3, Thomas J Kennedy7, Saul Tzipori6, J Stone Doggett8, Pablo Winzer9, Nicoleta Anghel9, Dennis Imhof9, Joachim Müller9, Andrew Hemphill9, Ignacio Ferre10, Roberto Sanchez-Sanchez10, Luis Miguel Ortega-Mora10, Kayode K Ojo2.
Abstract
This is a review of the development of bumped-kinase inhibitors (BKIs) for the therapy of One Health parasitic apicomplexan diseases. Many apicomplexan infections are shared between humans and livestock, such as cryptosporidiosis and toxoplasmosis, as well as livestock only diseases such as neosporosis. We have demonstrated proof-of-concept for BKI therapy in livestock models of cryptosporidiosis (newborn calves infected with Cryptosporidium parvum), toxoplasmosis (pregnant sheep infected with Toxoplasma gondii), and neosporosis (pregnant sheep infected with Neospora caninum). We discuss the potential uses of BKIs for the treatment of diseases caused by apicomplexan parasites in animals and humans, and the improvements that need to be made to further develop BKIs.Entities:
Keywords: Antiparastics; Apicomplexa; Kinase inhibitors
Mesh：
Substances：
Year: 2020 PMID： 33418437 PMCID： PMC8582285 DOI： 10.1016/j.vetpar.2020.109336
Source DB: PubMed Journal: Vet Parasitol ISSN： 0304-4017 Impact factor: 2.738